GlaxoSmithKline (China) Investment Co., Ltd. (hereinafter
"GSK China"), ranked 253rd on the list of Fortune Global
500 and the world's 7thbiggest pharmaceutical
company, recently caught widespread attention in China and abroad
when, on 11 July 2013, China's Ministry of Public Security
issued a notification stating that four senior executives from GSK
China were being probed on suspicion of commercial bribery and
other economic crimes. The media reports called the group of
executives "the 4 chariots" and said they were
"destructed".
Senior executives of multinational corporations have turned
their attention to one issue: which economic crimes are associated
with commercial bribery? What principles should senior executives
of multinational companies abide by in their business practice to
avoid criminal prosecution? To answer these questions, we need to
further analyze the boundaries of the crimes related to commercial
bribery.